This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164–1174.
Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230–239.
Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885–891.
Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25: 793–798.
Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23: 7024–7031.
Elter T, Gercheva-Kyuchukova L, Pylylpenko H, Robak T, Jaksic B, Rekhtman G et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol 2011; 12: 1204–1213.
Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M . Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 2009; 88: 121–132.
Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1756–1765.
Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol 2011; 29: 3559–3566.
Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956–964.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The trial was planned and conducted as an investigator-initiated trial by the GCLLSG. It was supported by research grants from Bayer-Schering AG and Genzyme. The GCLLSG receives financial support by the German Cancer Aid. TE, AE, SS, C-MW and MH received honoraria from Bayer-Schering AG and Genzyme. The other authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Elter, T., James, R., Busch, R. et al. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia 26, 2549–2552 (2012). https://doi.org/10.1038/leu.2012.129
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.129
This article is cited by
-
Individualisiertes Vorgehen zur Optimierung des Behandlungserfolges
Info Onkologie (2016)
-
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors
Leukemia (2014)
-
What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
Current Hematologic Malignancy Reports (2013)